Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 7/20 | 0.59 |
| ▸ | GAA | P10253 | 3/20 | 0.59 |
| ▸ | LOXL2 | Q9Y4K0 | 1/20 | 0.51 |
| ▸ | CDC25B | P30305 | 10/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.47 |
| ▸ | APAF1 | O14727 | 6/20 | 0.47 |
| ▸ | CASP3 | P42574 | 5/20 | 0.47 |
| ▸ | SENP8 | Q96LD8 | 5/20 | 0.47 |
| ▸ | SENP7 | Q9BQF6 | 5/20 | 0.47 |
| ▸ | SAE1 | Q9UBE0 | 4/20 | 0.47 |
| ▸ | UBA2 | Q9UBT2 | 4/20 | 0.47 |
| ▸ | HPGD | P15428 | 4/20 | 0.47 |
| ▸ | THRB | P10828 | 4/20 | 0.47 |
| ▸ | SENP6 | Q9GZR1 | 4/20 | 0.47 |
| ▸ | MAPT | P10636 | 3/20 | 0.47 |
| ▸ | UBE2I | P63279 | 2/20 | 0.47 |
| ▸ | RECQL | P46063 | 2/20 | 0.47 |
| ▸ | GALK1 | P51570 | 1/20 | 0.47 |
| ▸ | SMAD3 | P84022 | 1/20 | 0.47 |
| ▸ | ATG4B | Q9Y4P1 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL155511 | 0.86 | KDM4E (0.56) | KDM4EGAALOXL2CDC25BALDH1A1 | |
| SCHEMBL30249877 | 0.86 | KDM4E (0.56) | KDM4EGAALOXL2CDC25BALDH1A1 | |
| SCHEMBL155510 | 0.86 | KDM4E (0.56) | KDM4EGAALOXL2CDC25BALDH1A1 | |
| SCHEMBL14948305 | 0.83 | KDM4E (0.53) | KDM4EGAALOXL2CDC25BALDH1A1 | |
| SCHEMBL20849750 | 0.83 | LOXL2 (0.54) | KDM4EGAALOXL2CDC25BALDH1A1 | |
| SCHEMBL23668006 | 0.79 | CDC25B (0.54) | KDM4EGAALOXL2CDC25BALDH1A1 | |
| SCHEMBL23668005 | 0.79 | CDC25B (0.54) | KDM4EGAALOXL2CDC25BALDH1A1 | |
| SCHEMBL6601327 | 0.77 | LOXL2 (0.51) | KDM4EGAALOXL2CDC25BALDH1A1 | |
| SCHEMBL29488099 | 0.75 | KDM4E (1.00) | KDM4EGAALOXL2CDC25BALDH1A1 | |
| SCHEMBL824574 | 0.75 | KDM4E (1.00) | KDM4EGAALOXL2CDC25BALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2024108155-A2 | COMPOUNDS, COMPOSITIONS, AND METHODS | DENALI THERAPEUTICS INC. (US) | 2024-05-23 | — | — | WO | disclosed |
| US-20230128041-A1 | PARP1 INHIBITORS AND USES THEREOF | XINTHERA, INC. | 2023-04-27 | — | — | US | disclosed |
| US-10570116-B2 | 1,4-dicarbonyl-piperidyl derivatives | MERCK PATENT GMBH (DE) | 2020-02-25 | — | — | US | disclosed |
| US-20190092751-A1 | 1,4-DICARBONYL-PIPERIDYL DERIVATIVES | MERCK PATENT GMBH (DE) | 2019-03-28 | — | — | US | disclosed |
| EP-1566380-B1 | ISOQUINOLINE COMPOUNDS AND MEDICINAL USE THEREOF | MITSUBISHI TANABE PHARMA CORP (JP) | 2012-01-11 | — | — | EP | disclosed |
| US-7501412-B2 | Isoquinoline compounds and medicinal use thereof | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2009-03-10 | — | — | US | disclosed |
| US-20060094743-A1 | Isoquinoline compounds and medicinal use thereof | MITSUBISHI PHARMA CORPORATION (JP) | 2006-05-04 | — | — | US | disclosed |
| EP-1566380-A1 | ISOQUINOLINE COMPOUNDS AND MEDICINAL USE THEREOF | Mitsubishi Pharma Corporation (JP) | 2005-08-24 | — | — | EP | disclosed |
| US-6403608-B1 | ANTIINFLAMMATORY AND IMMUNE DISORDERS | CELLTECH R&D, LTD. (GB) | 2002-06-11 | — | — | US | disclosed |
| WO-1993014086-A1 | SUBSTITUTED 1-ISOQUINOLONE DERIVATIVES AS ANGIOTENSIN II ANTAGONISTS | SYNTEX (U.S.A.) INC. (US) | 1993-07-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060094743-A1 | Isoquinoline compounds and medicinal use thereof | PARP1, NQO1, PARP3 | KDM4E 3585/4885GAA 505/4885LOXL2 4474/4885 |
| US-10570116-B2 | 1,4-dicarbonyl-piperidyl derivatives | TNKS, TANK, TBKBP1 | KDM4E 125/4885GAA 1276/4885LOXL2 2227/4885 |
| US-20230128041-A1 | PARP1 INHIBITORS AND USES THEREOF | PARP1, PARP11, PARP12 | KDM4E 1632/4885GAA 1804/4885LOXL2 2535/4885 |
| US-20190092751-A1 | 1,4-DICARBONYL-PIPERIDYL DERIVATIVES | TNKS, TANK, TBKBP1 | KDM4E 125/4885GAA 1276/4885LOXL2 2227/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.